M. Eileen Dolan, PhD

Professor of Medicine, Section of Hematology/Oncology

Program Co-Leader, Clinical and Experimental Therapeutics, The University of Chicago Comprehensive Cancer Center

Chair, Committee on Clinical Pharmacology and Pharmacogenomics

Chair, Committee on Reappointment of Assistant Professors

Dr. M. Eileen Dolan is a translational scientist with expertise in both preclinical models and clinical research. She works closely with physicians to evaluate pharmacogenomic endpoints in clinical trials. Dr. Dolan is well known for her work in developing modulators of DNA repair to enhance chemotherapy. Over the last decade, she has concentrated her research in the area of cancer pharmacogenomics. She is a leader in developing cell-based methods to identify genetic variants contributing to chemotherapeutic response and toxicity. Her laboratory was the first to demonstrate that chemotherapeutic induced cytotoxicity is a heritable trait, and the first to utilize lymphoblastoid cell lines as a model to demonstrate inter-ethnic differences in sensitivity to chemotherapy that recapitulates what is observed clinically for these drugs. Her laboratory developed a “triangle approach” to identify genetic variants associated with chemotherapeutic induced cytotoxicity, a model that has been adopted by other researchers within pharmacogenomics. She is well-funded as the principal investigator of an RO1 grant dedicated to identifying genetic variants associated with chemotherapy, a project within the University of Chicago Breast Cancer SPORE, and a project within the Pharmacogenetics of Anticancer Agents Research Group (www.pharmacogenetics.org).

She has mentored 18 clinical and post-doctoral fellows (includes both Hematology-Oncology and Clinical Pharmacology and Pharmacogenomics), 4 graduate students, and 7 medical students. Six clinical pharmacology fellows under her direction received national, peer-reviewed funding for their research project while working in the laboratory. In addition, her trainees received over 22 national awards and/or oral presentations at national meetings. Numerous fellows have gone on to faculty positions.

Selected Publications from 2010 – 2011

  • Wen Y, Gorsic LK, Wheeler HE, Ziliak DM, Huang RS, Dolan ME. Chemotherapeutic-Induced Apoptosis – A Phenotype for Pharmacogenomics Studies. Pharmacogenetics and Genomics [in press], 2011.
  • Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ, Dolan ME. Genome-Wide Local Ancestry Approach Identifies Genes and Variants Associated with Chemotherapeutic Susceptibility in African Americans. PLoS One [in press], 2011.
  • Gamazon ER, Huang RS, Dolan ME, Cox NJ. Copy Number Polymorphisms and Anticancer Pharmacogenomics. Genome Biol 12:R46 [Epub ahead of print], 2011.
  • Mitra AK, Crews K, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz J, Ribeiro R, Lamba JK. Genetic variants in NT5C2 are associated with its expression and cytarabine sensitivity in HapMap cell lines and in AML patients. J Pharmacol Exp Ther [Epub ahead of print], 2011.
  • Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ. SCAN: SNP and Copy number Annotation. Bioinformatics 26: 259-262, 2010.
  • Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait Associated SNPs Are More Likely to be eQTLs: Annotation to Enhance Discovery from GWAS. PLoS Genet  6:e1000888, 2010.
  • Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ.  PACdb: A Database for Cell-based Pharmacogenomics. Pharmacogenetics and Genomics 20: 269-273, 2010.
  • Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic Drug Susceptibility Associated SNPs are Enriched in Expression Quantitative Trait Loci.  PNAS 107: 9287-9292, 2010.


  • Wilke R and Dolan ME. Gene-Based Drug Prescribing. JAMA [in press], 2011.
  • Innocenti F, Cox NJ, Dolan ME. The use of genomic information to optimize cancer chemotherapy. Seminars in Oncology 38:186-195, 2011.
  • Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, LeBeau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Seminars in Oncology 38:215-224, 2011.
  • Pinto N and Dolan ME. Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes. Current Drug Metabolism 12:487-497, 2011.

Selected Presentations

  • “Whole Genome Approaches to Identifying Pharmacogenomic Markers in Oncology”
    Invited Speaker at the 9th International Conference of Asian Clinical Oncology Society
    Gifu, Japan
    August 2010
  • “Pharmacogenomics of Anti-Cancer Drugs”
    Invited Speaker at the 19th Annual Beaumont Hospitals Molecular Pathology Symposium
    Troy, MI
    September 2010
  • “Pharmacogenomics Discovery using Cell-Based Models”
    Invited Speaker at the NCI Cancer Pharmacogenomics Workshop
    Bethesda, MD
    October 2010
  • “Pharmacogenetics of Anticancer Agents”
    Invited Speaker at Midwestern University
    Downers Grove, IL
    December 2010
  • “Whole Genome Approaches to Identify Pharmacogenomic Markers in Oncology”
    Invited Speaker at Personalized Cancer Medicine: Towards Individualized Cancer Treatment Symposium
    February 2011
  • “Whole Genome Approaches to Identify Pharmacogenomic Markers in Oncology”
    Invited Speaker at University of Pittsburg 25th Anniversary Cancer Genomics and the Impact of Next Generation Sequencing Symposia
    Pittsburg, PA
    March 2011
  • “Whole Genome Approaches to Identify Pharmacogenomic Markers in Oncology”
    Invited Speaker at University of Illinois
    Chicago, IL
    April 2011